SCHEMBL268283

SCHEMBL268283

CCOC(=O)c1cc(N2CCCCC2)ccc1[N+](=O)[O-]

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.61
ALDH1A1 P00352 8/20 0.61
HPGD P15428 2/20 0.60
SIRT6 Q8N6T7 1/20 0.60
LMNA P02545 2/20 0.54
CYP1A2 P05177 4/20 0.53
CYP2C19 P33261 4/20 0.53
CYP2C9 P11712 3/20 0.53
L3MBTL1 Q9Y468 1/20 0.52
KMT2A Q03164 2/20 0.51
MEN1 O00255 1/20 0.49
CYP3A4 P08684 1/20 0.49
GPR174 Q9BXC1 1/20 0.48
HTT P42858 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13162443 0.89 SIRT6 (0.76) MAPTALDH1A1SIRT6LMNAL3MBTL1
SCHEMBL23316412 0.88 SIRT6 (0.61) MAPTALDH1A1HPGDSIRT6LMNA
SCHEMBL19677556 0.88 MAPT (0.70) MAPTALDH1A1HPGDSIRT6LMNA
SCHEMBL3463899 0.88 MAPT (0.59) MAPTALDH1A1HPGDSIRT6LMNA
SCHEMBL44878 0.86 SIRT6 (0.79) MAPTALDH1A1HPGDSIRT6LMNA
SCHEMBL20509684 0.85 SIRT6 (0.81) MAPTALDH1A1HPGDSIRT6LMNA
SCHEMBL13184024 0.82 SIRT6 (0.55) MAPTALDH1A1HPGDSIRT6LMNA
SCHEMBL23316379 0.82 MAPT (0.59) MAPTALDH1A1SIRT6LMNACYP1A2
SCHEMBL11736626 0.82 MAPT (0.76) MAPTALDH1A1HPGDSIRT6LMNA
SCHEMBL40110 0.80 HPGD (0.62) MAPTALDH1A1HPGDSIRT6LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 MAPT 4195/4885ALDH1A1 3022/4885HPGD 2509/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 MAPT 4648/4885ALDH1A1 2872/4885HPGD 2407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.